HONG KONG – Tokyo-based Chugai Pharmaceutical Co. Ltd. has launched a subcutaneous injection of Enspryng (satralizumab) in Japan to prevent relapses of neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica (NMO).
The FDA came through at last for Athlone, Ireland-based Innocoll Holdings Ltd., greenlighting the drug-device combo Xaracoll (bupivacaine HCl) for acute postsurgical pain relief for up to 24 hours in adults after open inguinal hernia repair.
New research is set to expand the therapeutic time window for stroke treatment, while also contributing to the basic research understanding that stroke pathogenesis involves much more than acute disruption of blood flow.
Neurovascular bioelectronics medicine company Synchron Inc. has received good news in the form of a breakthrough device designation for its Stentrode. The U.S. FDA granted the designation for the fully implantable medical device that can translate brain activity or stimulate the nervous system from inside a blood vessel. As a bonus for patients, the device does not require open brain surgery. “As this is a first-of-its-kind device, we look forward to working closely with the FDA to prioritize development of the Stentrode and ensure access for patients with paralysis, as well as lay the groundwork for future indications for brain-computer interfaces,” said Thomas Oxley, CEO of Synchron.
Keeping you up to date on recent developments in neurology, including: Blood-based test used to predict who is likely to develop psychotic disorders; Study could lead to more personalized choices for OCD treatment; Nerve cells differ before birth in people with ASD.
A synthetic extracellular scaffolding protein (ESP) has been shown to restore synaptic functions, motor coordination, memory and locomotion in mouse models of cerebellar ataxia, Alzheimer's disease (AD), and spinal cord injury (SCI), in a collaborative European and Japanese study.
Privately held Alzheon Inc. picked up a $47 million grant from the NIH’s National Institute on Aging that will last over five years to support a phase III clinical trial of its oral brain-penetrant small molecule ALZ-801 to treat Alzheimer’s disease.
Neuroone Medical Technology Corp.’s thin film, high definition cortical electrode technology, Evo, can record, monitor, ablate, and stimulate brain tissue for up to 30 days, potentially transforming neurosurgical procedures used to treat epilepsy, Parkinson’s disease, chronic pain, and other conditions.
Now that Ovid Therapeutics Inc.’s and Takeda Pharmaceutical Co. Ltd.’s phase II study of soticlestat in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) has produced positive top-line data, Ovid is planning the drug’s phase III clinical trial while pricing a $50 million common stock offering.
Moving to build out its central nervous system (CNS) portfolio with an eye to what Acadia Pharmaceuticals Inc. CEO Steve Davis called an "urgent need for new approaches to treat pain without causing addiction," the company is acquiring privately-held Cersci Therapeutics Inc. for $52.5 million, primarily in stock.